# ![@EnsysceBio1 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1922638830609281024.png) @EnsysceBio1 Ensysce Biosciences

Ensysce Biosciences posts on X about $ensc, in the, ceo, science the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1922638830609281024/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1922638830609281024/c:line/m:interactions.svg)

- [--] Week [---] +10%
- [--] Month [-----] +143%

### Mentions: [--] [#](/creator/twitter::1922638830609281024/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1922638830609281024/c:line/m:posts_active.svg)


### Followers: [--] [#](/creator/twitter::1922638830609281024/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1922638830609281024/c:line/m:followers.svg)

- [--] Week [--] +9.10%

### CreatorRank: undefined [#](/creator/twitter::1922638830609281024/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1922638830609281024/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance) 

**Social topic influence**
[$ensc](/topic/$ensc), [in the](/topic/in-the), [ceo](/topic/ceo), [science](/topic/science), [strong](/topic/strong), [ip](/topic/ip), [cmo](/topic/cmo), [reduce](/topic/reduce), [the most](/topic/the-most), [regulatory](/topic/regulatory)

**Top accounts mentioned or mentioned by**
[@painweek](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Next Week: @PAINWeek is the largest pain conference in the world where experts meet to share knowledge to enhance patient care. The Ensysce Biosciences-sponsored symposium Pain Management RE-Invented: A New Era for Analgesia' will take place in Las Vegas on September 3rd [----]. Webcast: $ENSC #EnsysceBiosciences #PAINWeek #Conference https://conference.painweek.org/ https://conference.painweek.org/"  
[X Link](https://x.com/EnsysceBio1/status/1961039139740017073)  2025-08-28T12:12Z [--] followers, [--] engagements


"$ENSC Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek [----] Symposium View key takeaways from its standing-room-only symposium Pain Management RE-Invented: A New Era for Analgesia held September [--] [----] at PAINWeek in Las Vegasthe worlds largest pain management conference. https://finance.yahoo.com/news/ensysce-biosciences-showcases-urgent-safer-120000471.html https://finance.yahoo.com/news/ensysce-biosciences-showcases-urgent-safer-120000471.html"  
[X Link](https://x.com/EnsysceBio1/status/1963615090172735938)  2025-09-04T14:48Z [--] followers, [--] engagements


"How is the Ensysce Solution Different $ENSC Ensysces platforms use chemical safety switches designed to transform pain treatment: 🔹 TAAP (Trypsin-Activated Abuse Protection): Reduces abuse risk by controlling activation and release. 🔹 MPAR (Multi-Pill Abuse Resistance): Adds overdose protection turning off release if too many pills are taken. Together these technologies aim to provide safer smarter pain relief. 📊 To read more about our solutions visit the Ensysce August [----] Investor Presentation:"  
[X Link](https://x.com/EnsysceBio1/status/1971242302787010624)  2025-09-25T15:56Z [--] followers, [----] engagements


"$ENSC Highlights from Ensysce Biosciences sponsored symposium Pain Management RE-Invented: A New Era for Analgesia at PAINWeek [----] are now available on our website. The presentation showcases Ensysces innovative TAAP and MPAR technologies PF614 and PF614-MPAR which use the bodys own chemistry to switch on pain relief at proper doses and switch off opioid release in the event of an overdose."  
[X Link](https://x.com/EnsysceBio1/status/1977680766617137314)  2025-10-13T10:20Z [--] followers, [---] engagements


"$ENSC Ensysce's Media/Science Center offers a comprehensive collection of resources showcasing our innovative approaches to pain management and opioid safety. Featured content includes: Videos: Insights from experts like Drs. Jeff Gudin Richard Dart Jessica McCoun and William Schmidt are discussing pain PF614 MPAR and overdose protection. Podcasts: In-depth discussions on TAAP MPAR and next-generation analgesics. Abstracts & Manuscripts: Access to clinical evaluations development studies and research papers on PF614 and related technologies. These materials provide valuable information for"  
[X Link](https://x.com/EnsysceBio1/status/1978828043175997858)  2025-10-16T14:19Z [--] followers, [---] engagements


"$ENSC Reimagining Pain Relief with TAAP Technology Ensysces proprietary TAAP (Trypsin-Activated Abuse Protection) platform introduces a new standard in opioid safety through a two-step internal activation process. 🔹 Activated only in the gut: TAAP opioids require the digestive enzyme trypsin to release the active ingredient preventing activation if crushed snorted injected or chewed. 🔹 Extended relief: Provides over [--] hours of pain control approximately 30% longer than standard abuse-deterrent formulations enabling true twice-daily dosing. 🔹 FDA Fast Track designation: Recognized for its"  
[X Link](https://x.com/EnsysceBio1/status/1980921679141351547)  2025-10-22T08:58Z [--] followers, [---] engagements


"Our proprietary TAAP (Trypsin-Activated Abuse Protection) platform which has received FDA Fast Track designation has the potential to redefine opioid safety. Unlike traditional abuse-deterrent formulations TAAP opioids are only activated by trypsin a digestive enzyme found in the gut making them resistant to manipulation by crushing chewing snorting or injection. With a two-step activation process and 12+ hours of pain relief TAAP aims to deliver effective treatment while minimizing the risk of misuse and abuse. This breakthrough technology represents a major step forward in developing safer"  
[X Link](https://x.com/EnsysceBio1/status/1986000467101458477)  2025-11-05T09:19Z [--] followers, [--] engagements


"$ENSC Chronic pain affects roughly [--] million U.S. adults representing one of the largest unmet medical needs in the country. Current opioid options remain effective for severe pain but their risk profile limits use and exposes patients to misuse and overdose. Ensysce is developing chemistry-driven safety mechanisms: TAAP prodrugs activate only when exposed to intestinal trypsin reducing risk from tampering or non-oral use. MPAR introduces a controlled inhibitor that reduces opioid release when an excess of capsules is taken at once. The goal is simple: deliver therapeutic analgesia while"  
[X Link](https://x.com/EnsysceBio1/status/1989281919188529331)  2025-11-14T10:39Z [--] followers, [--] engagements


"Ensysce $ENSC Q3 results reflect higher R&D as PF614 and PF614-MPAR advance through Phase [--] and preclinical work while G&A stayed stable. Federal grant revenue tracked PF614-MPAR reimbursable work. Net loss was $3.7M and a $4M preferred raise strengthened the balance sheet"  
[X Link](https://x.com/EnsysceBio1/status/1990842559053062487)  2025-11-18T18:00Z [--] followers, [--] engagements


"Ensysce $ENSC Q3 update: PF614-301 Phase [--] in severe pain is now underway advancing the TAAP prodrug platform while PF614-MPAR moves forward in FDA discussions on overdose-protection labeling reinforcing its focus on novel safer opioid analgesia"  
[X Link](https://x.com/EnsysceBio1/status/1990842605047816243)  2025-11-18T18:00Z [--] followers, [--] engagements


"$ENSC Q3 included developments supporting long-term readiness for clinical execution and regulatory submissions. Initiation of Phase [--] PF614-301 with engagement of Rho Inc. to ensure consistent operational quality and endpoint management. Alignment with FDA on next steps for PF614-MPAR including pursuit of overdose-protection labeling and a streamlined 505(b)(2) approach. Advancement of the OUD program under multi-year HEAL grant support with selection of lead candidate PF9001. Internal focus on CMC quality systems and data processes required for future NDA preparation. Operational activities"  
[X Link](https://x.com/EnsysceBio1/status/1991896531054776701)  2025-11-21T15:48Z [--] followers, [--] engagements


"$ENSC received a Notice of Allowance from the Brazilian Patent Office covering additional opioid families using TAAP and MPAR technologies. This strengthens our global IP estate and supports next-generation analgesics focused on safety. Read more: https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio"  
[X Link](https://x.com/EnsysceBio1/status/2014088415612969031)  2026-01-21T21:31Z [--] followers, [--] engagements


"$ENSC Listen to Ensysce Biosciences CEO on the NanoCap Podcast address one of medicines toughest problems: delivering powerful pain relief without compromising safety"  
[X Link](https://x.com/EnsysceBio1/status/2014436228230246560)  2026-01-22T20:33Z [--] followers, [--] engagements


"$ENSC Dr. William Schmidt CMO at Ensysce Biosciences on the companys global opioid patent expansion: Applying MPAR across TAAP-designed opioids may reduce abuse and help prevent overdose while preserving effective pain relief"  
[X Link](https://x.com/EnsysceBio1/status/2014753965485776921)  2026-01-23T17:35Z [--] followers, [--] engagements


"$ENSC Ensysce Biosciences participated in NANOCAP Podcast and the conversation focused on one of the most critical and often misunderstood challenges in modern medicine: pain management. During the transmition our team shared Ensysces mission to transform the way pain is treated so patients no longer have to choose between effective relief and safety. While pain plays an essential biological role as a warning signal it becomes devastating when the body cannot switch it off resulting in severe acute or chronic pain that can profoundly impact quality of life. The conversation highlighted the"  
[X Link](https://x.com/EnsysceBio1/status/2015857590010339747)  2026-01-26T18:41Z [--] followers, [--] engagements


"$ENSC Today ENSC was pleased to share that our pivotal Phase [--] trial evaluating PF614 for the treatment of moderate to severe post-surgical pain reach an important clinical milestone. The trial after beginning last Dec. [----] has reached 50% enrollment of subjects targeted for interim review. This reflects strong execution across multiple U.S. clinical sites as well as clear demand for better acute pain solutions. Importantly with near term interim data PF614s clinical profile approaches validation. For the company this milestone represents tangible progress toward a late stage asset in a"  
[X Link](https://x.com/EnsysceBio1/status/2016563873155826008)  2026-01-28T17:27Z [--] followers, [---] engagements


"$ENSC Innovation only matters if it reaches patients. On the NanoCap Podcast Ensysce CEO Dr. Lynn Kirkpatrick discussed the discipline behind advancing novel pain therapiesnow validated by progression to Phase [--]. With FDA Fast Track and Breakthrough Therapy Designations Ensysce is executing with late-stage focus regulatory alignment and long-term value creation in mind with TAAP and MPAR platform technology. https://twitter.com/i/web/status/2018423572100735406 https://twitter.com/i/web/status/2018423572100735406"  
[X Link](https://x.com/anyuser/status/2018423572100735406)  2026-02-02T20:37Z [--] followers, [---] engagements


"$ENSC As we move into [----] priorities remain focused on execution including continued enrollment in the PF614-301 Phase [--] study and advancement of PF614-MPAR supported by ongoing FDA engagement. Updates will be shared via official IR channels"  
[X Link](https://x.com/EnsysceBio1/status/2011534882082840684)  2026-01-14T20:24Z [--] followers, [--] engagements


"$ENSC Ensysce is opening the floor for your questions in our upcoming AMA. What would you like to know about our science our progress or our vision for safer pain management Share your questions below and our team will address them in the session. https://youtu.be/AcczBHcNNkw https://youtu.be/AcczBHcNNkw"  
[X Link](https://x.com/anyuser/status/2014436596792127734)  2026-01-22T20:34Z [--] followers, [--] engagements


"$ENSC Severe pain still demands opioid-level efficacy. No alternative has matched it. Ensysces solution: engineer safety directly into the drugs chemistry using the body itself to control delivery. This chemistry-first approach to abuse and overdose protection with TAAP and MPAR is scalable and differentiatedpositioning Ensysce to reshape the future of pain therapeutics. https://twitter.com/i/web/status/2015851023282184348 https://twitter.com/i/web/status/2015851023282184348"  
[X Link](https://x.com/EnsysceBio1/status/2015851023282184348)  2026-01-26T18:15Z [--] followers, [--] engagements


"$ENSC PF614 was designed to deliver opioid level pain relief while reducing the abuse and misuse risks associated with conventional opioids a persistent challenge. PF614 a TAAP-opioid remains inactive until swallowed enabling extended-release analgesia through twice-daily dosing while limiting tampering. . The Phase [--] enrollment milestone reinforces our confidence in PF614s potential and our broader mission to modernize pain treatment through smarter and safer pharmaceutical design. https://twitter.com/i/web/status/2016987545393852765 https://twitter.com/i/web/status/2016987545393852765"  
[X Link](https://x.com/anyuser/status/2016987545393852765)  2026-01-29T21:31Z [--] followers, [---] engagements


"$ENSC Leadership mattersespecially in drug development. On the NanoCap Podcast CEO Dr. Lynn Kirkpatrick shared how her background in medicinal chemistry pharmacology and drug development shapes Ensysces strategy: no shortcuts only great science and execution. TAAP and MPAR are designed to preserve opioid efficacy while improving safetyand to prevent acute pain from turning chronic. This is purpose-built innovation led by experience aimed at impact. https://twitter.com/i/web/status/2018757533746299237 https://twitter.com/i/web/status/2018757533746299237"  
[X Link](https://x.com/anyuser/status/2018757533746299237)  2026-02-03T18:44Z [--] followers, [---] engagements


"$ENSC In [----] [-----] overdose deaths in the U.S. involved opioids representing 76% of all drug overdose fatalities. Despite a 12% YoY decline in prescription opioid deaths [--] people per day still die from prescribed opioid overdoses"  
[X Link](https://x.com/anyuser/status/2022429499909116324)  2026-02-13T21:55Z [--] followers, [--] engagements


"$ENSC Ensysce Biosciences is developing next-generation abuse-deterrent technologies designed to combine effective analgesia with built-in overdose protection advancing a differentiated approach to opioid safety"  
[X Link](https://x.com/anyuser/status/2022429501641347563)  2026-02-13T21:55Z [--] followers, [--] engagements


"$ENSC Leadership mattersespecially in drug development. On the NanoCap Podcast CEO Dr. Lynn Kirkpatrick shared how her background in medicinal chemistry pharmacology and drug development shapes Ensysces strategy: no shortcuts only great science and execution. TAAP and MPAR are designed to preserve opioid efficacy while improving safetyand to prevent acute pain from turning chronic. This is purpose-built innovation led by experience aimed at impact. https://twitter.com/i/web/status/2018757533746299237 https://twitter.com/i/web/status/2018757533746299237"  
[X Link](https://x.com/anyuser/status/2018757533746299237)  2026-02-03T18:44Z [--] followers, [---] engagements


"$ENSC Innovation only matters if it reaches patients. On the NanoCap Podcast Ensysce CEO Dr. Lynn Kirkpatrick discussed the discipline behind advancing novel pain therapiesnow validated by progression to Phase [--]. With FDA Fast Track and Breakthrough Therapy Designations Ensysce is executing with late-stage focus regulatory alignment and long-term value creation in mind with TAAP and MPAR platform technology. https://twitter.com/i/web/status/2018423572100735406 https://twitter.com/i/web/status/2018423572100735406"  
[X Link](https://x.com/anyuser/status/2018423572100735406)  2026-02-02T20:37Z [--] followers, [---] engagements


"$ENSC PF614 was designed to deliver opioid level pain relief while reducing the abuse and misuse risks associated with conventional opioids a persistent challenge. PF614 a TAAP-opioid remains inactive until swallowed enabling extended-release analgesia through twice-daily dosing while limiting tampering. . The Phase [--] enrollment milestone reinforces our confidence in PF614s potential and our broader mission to modernize pain treatment through smarter and safer pharmaceutical design. https://twitter.com/i/web/status/2016987545393852765 https://twitter.com/i/web/status/2016987545393852765"  
[X Link](https://x.com/anyuser/status/2016987545393852765)  2026-01-29T21:31Z [--] followers, [---] engagements


"$ENSC Today ENSC was pleased to share that our pivotal Phase [--] trial evaluating PF614 for the treatment of moderate to severe post-surgical pain reach an important clinical milestone. The trial after beginning last Dec. [----] has reached 50% enrollment of subjects targeted for interim review. This reflects strong execution across multiple U.S. clinical sites as well as clear demand for better acute pain solutions. Importantly with near term interim data PF614s clinical profile approaches validation. For the company this milestone represents tangible progress toward a late stage asset in a"  
[X Link](https://x.com/EnsysceBio1/status/2016563873155826008)  2026-01-28T17:27Z [--] followers, [---] engagements


"$ENSC Ensysce Biosciences participated in NANOCAP Podcast and the conversation focused on one of the most critical and often misunderstood challenges in modern medicine: pain management. During the transmition our team shared Ensysces mission to transform the way pain is treated so patients no longer have to choose between effective relief and safety. While pain plays an essential biological role as a warning signal it becomes devastating when the body cannot switch it off resulting in severe acute or chronic pain that can profoundly impact quality of life. The conversation highlighted the"  
[X Link](https://x.com/EnsysceBio1/status/2015857590010339747)  2026-01-26T18:41Z [--] followers, [--] engagements


"$ENSC Severe pain still demands opioid-level efficacy. No alternative has matched it. Ensysces solution: engineer safety directly into the drugs chemistry using the body itself to control delivery. This chemistry-first approach to abuse and overdose protection with TAAP and MPAR is scalable and differentiatedpositioning Ensysce to reshape the future of pain therapeutics. https://twitter.com/i/web/status/2015851023282184348 https://twitter.com/i/web/status/2015851023282184348"  
[X Link](https://x.com/EnsysceBio1/status/2015851023282184348)  2026-01-26T18:15Z [--] followers, [--] engagements


"$ENSC Dr. William Schmidt CMO at Ensysce Biosciences on the companys global opioid patent expansion: Applying MPAR across TAAP-designed opioids may reduce abuse and help prevent overdose while preserving effective pain relief"  
[X Link](https://x.com/EnsysceBio1/status/2014753965485776921)  2026-01-23T17:35Z [--] followers, [--] engagements


"$ENSC Ensysce is opening the floor for your questions in our upcoming AMA. What would you like to know about our science our progress or our vision for safer pain management Share your questions below and our team will address them in the session. https://youtu.be/AcczBHcNNkw https://youtu.be/AcczBHcNNkw"  
[X Link](https://x.com/anyuser/status/2014436596792127734)  2026-01-22T20:34Z [--] followers, [--] engagements


"$ENSC Listen to Ensysce Biosciences CEO on the NanoCap Podcast address one of medicines toughest problems: delivering powerful pain relief without compromising safety"  
[X Link](https://x.com/EnsysceBio1/status/2014436228230246560)  2026-01-22T20:33Z [--] followers, [--] engagements


"$ENSC received a Notice of Allowance from the Brazilian Patent Office covering additional opioid families using TAAP and MPAR technologies. This strengthens our global IP estate and supports next-generation analgesics focused on safety. Read more: https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio https://ir.ensysce.com/news/press-releases/detail/208/ensysce-biosciences-expands-global-opioid-patent-portfolio"  
[X Link](https://x.com/EnsysceBio1/status/2014088415612969031)  2026-01-21T21:31Z [--] followers, [--] engagements


"$ENSC As we move into [----] priorities remain focused on execution including continued enrollment in the PF614-301 Phase [--] study and advancement of PF614-MPAR supported by ongoing FDA engagement. Updates will be shared via official IR channels"  
[X Link](https://x.com/EnsysceBio1/status/2011534882082840684)  2026-01-14T20:24Z [--] followers, [--] engagements


"$ENSC ADHD affects millions yet stimulant medications carry risks of misuse dependence and overdose. Ensysces ADHD program pairs amphetamine efficacy with built-in abuse deterrence and overdose protection through its TAAP and MPAR technologies"  
[X Link](https://x.com/anyuser/status/2010827353992135116)  2026-01-12T21:32Z [--] followers, [---] engagements


"$ENSC EU allowance for PF8026 highlights TAAP and MPAR across CNS. Ensysces prodrug approach blocks common abuse routes and adds multi-pill overdose protection validated clinically supporting safer ADHD candidates. Read more about this incredible milestone here: https://ir.ensysce.com/news/press-releases/detail/207/ensysce-biosciences-receives-eu-patent-expanding-its https://ir.ensysce.com/news/press-releases/detail/207/ensysce-biosciences-receives-eu-patent-expanding-its"  
[X Link](https://x.com/anyuser/status/2010031455984857355)  2026-01-10T16:50Z [--] followers, [--] engagements


"$ENSC The highlight of [----] was reaching a pivotal milestone the initiation of patient enrollment in the Phase [--] clinical trial of PF614 a next-generation opioid designed to deliver potent pain relief with built-in abuse protection. This critical step displays our continued advancement towards commercialization. This achievement marks: Progress into late-stage development advancing PF614 closer to potential regulatory submission and market entry a key inflection point for a clinical-stage biotech. Validation of our science demonstrating confidence in both the design of PF614 and the strength"  
[X Link](https://x.com/anyuser/status/2006897525136175294)  2026-01-02T01:17Z [--] followers, [--] engagements


"Watch: $ENSC Ensysce Biosciences participated in PAINWeek [----] the worlds largest pain management conference highlighting the urgent need for safer next-generation pain treatments. During its symposium Pain Management Re-Invented Ensysce convened leading pain experts to discuss how innovative opioid technologies can deliver effective analgesia while reducing the risks of misuse abuse and overdose. This session summarized Ensysces mission and its TAAP and MPAR platforms designed to improve patient safety. 🎥 Watch Ensysces PAINWeek [----] participation and symposium highlights here:"  
[X Link](https://x.com/anyuser/status/2005846011076567123)  2025-12-30T03:38Z [--] followers, [---] engagements


"PF614s design is a potential game-changer in post-surgical pain management combining strong efficacy with enhanced safety features. #Ensysce #PF614 #OpioidSafety #PainManagement #BiotechNews #NextGenTherapy $ENSC"  
[X Link](https://x.com/anyuser/status/2003680362145436002)  2025-12-24T04:13Z [--] followers, [--] engagements


"For the first time in decades opioid innovation is evolving. Ensysce is developing a new class of opioids designed to deliver powerful pain relief with low abuse potential and a reduced risk of overdose. Building on thousands of years of opioid use from early identification to abuse-deterrent formulations Ensysces proprietary TAAP and MPAR technologies represent the next step forward using clever chemistry to change how pain relief is delivered. We believe this Next Generation of opioid analgesia has the potential to restore prescriber confidence and improve outcomes for patients. #Ensysce"  
[X Link](https://x.com/anyuser/status/2003404736247279903)  2025-12-23T09:58Z [--] followers, [--] engagements


"Our recently announced pivotal milestone is highly encouraging as the first patient has been enrolled in the PF614 Phase3 program: Multicenter randomized double-blind placebo-controlled trial for moderate to severe post-abdominoplasty pain. Enrollment commenced at leading clinical sites under expert principal investigators. Marks a key step toward redefining post-surgical opioid therapy with next-generation PF614 designed to provide reliable pain relief with a unique safety profile. These developments highlight Ensysces commitment to advancing safer more effective pain management for millions"  
[X Link](https://x.com/anyuser/status/2003072542198927633)  2025-12-22T11:58Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing